Loading...

ORGO - Organogenesis Holdings Inc.

Analyst Coverage Initiated Signal for 02-07-2024
Analyst Coverage Initiated: ORGO rating Overweight by Cantor Fitzgerald
Price Target: $5


Loading Chart ORGO

Stock Signal Information


Signal

Analyst Coverage Initiated: ORGO rating Overweight by Cantor Fitzgerald
Price Target: $5
Report Date: 02-07-2024
Symbol: ORGO - Organogenesis Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Analyst Coverage Initiated: ORGO rating Overweight by Cantor Fitzgerald
Price Target: $5

  ORGO Technical Analysis

Company Contact

Organogenesis Holdings Inc. (ORGO)
85 Dan Rd
Canton, MASSACHUSETTS 02021
Phone: 17815750775
Website: http://organogenesis.com
CEO: Mr. Gary S. Gillheeney Sr.

ORGO, Organogenesis Holdings Inc.

ORGO Organogenesis Holdings Inc. Logo Image

NASDAQ, Nasdaq Capital Market


Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 700 full-time employees. The firm focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company also provides integrated healing solutions that substantially improve medical outcomes. The Company’s advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The firm is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.